Vasculitis & polymyalgia rheumatica
Diagnostic accuracy of serum biomarkers to identify giant cell arteritis in patients with polymyalgia rheumatica
Authors' conclusion
Combined serum biomarkers such as CXCL9/IL-6 and MMP-3/sCD141 could help identify GCA in patients with isolated PMR.
Study context
- Population
- Patients with isolated polymyalgia rheumatica (PMR) or PMR/giant cell arteritis (GCA) overlap, sampled before starting GC
- Participants
- 29 vs 45
- Comparison
- PMR/GCA overlap vs isolated PMR
- GCAn = 29
- Isolated PMRn = 45reference
- Outcome
- Serum biomarkers and ratios to identify GCA
Methodological detailsLuminex assays, blood samples before glucocorticoids
- Luminex assays
- Blood samples before glucocorticoids
Performance
As reported in the abstract
- AUC of sCD141, CXCL9, IL-6 and MMP-3 separately: none >0.7; combinations gave higher diagnostic accuracy
- GCA vs Isolated PMR: P = 0.002
- GCA vs Isolated PMR: P = 0.002
- GCA vs Isolated PMR: P = 0.01
- GCA vs Isolated PMR: P = 0.004
- GCA vs Isolated PMR: P = 0.0001
- GCA vs Isolated PMR: P < 0.0001
Further findings
Diagnostic accuracy in subclinical GCA
- sCD141 AUC
- 0.81
- MMP-3/sCD141 ratio AUC
- 0.77
Original publication
Diagnostic accuracy of serum biomarkers to identify giant cell arteritis in patients with polymyalgia rheumatica. RMD Open. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →